Crispr Therapeutics AG's market cap is currently ―. The company's EPS TTM is $-8.37; its P/E ratio is -5.19; Crispr Therapeutics AG is scheduled to report earnings on May 9, 2023, and the estimated EPS forecast is $-1.92. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	$ 6.00K	$ 94.00K	$ 158.00K	$ 178.00K	$ 12.90M
Gross Profit	$ -6.82M	$ -38.77M	$ -33.76M	$ -30.47M	-
EBIT	$ -131.54M	$ -182.39M	$ -183.26M	$ -175.97M	$ -145.70M
EBITDA	$ -125.69M	$ -177.37M	$ -175.99M	$ -169.93M	$ -139.44M
Net Income Common Stockholders	$ -110.58M	$ -174.55M	$ -185.83M	$ -179.22M	$ -141.25M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 1.82B	$ 1.90B	$ 2.07B	$ 2.22B	$ 2.38B
Total Assets	$ 2.24B	$ 2.35B	$ 2.46B	$ 2.61B	$ 2.75B
Total Debt	$ 244.02M	$ 242.16M	$ 242.43M	$ 238.98M	$ 225.03M
Net Debt	$ -1.57B	$ -1.65B	$ -1.82B	$ -1.98B	$ -2.15B
Total Liabilities	$ 367.58M	$ 399.40M	$ 372.53M	$ 361.26M	$ 352.42M
Stockholders Equity	$ 1.88B	$ 1.95B	$ 2.09B	$ 2.24B	$ 2.40B
Cash Flow	-
Free Cash Flow	$ -119.52M	$ -111.23M	$ -151.59M	$ -150.59M	$ -95.22M
Operating Cash Flow	$ -113.33M	$ -105.22M	$ -141.96M	$ -135.24M	$ -86.04M
Investing Cash Flow	$ -175.53M	$ 87.46M	$ -56.07M	$ -114.52M	$ -8.72M
Financing Cash Flow	$ 2.48M	$ 15.11M	$ 10.35M	$ 10.65M	$ 6.30M

Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Income Statement >

Crispr Therapeutics AG Debt to Assets

Balance Sheet >

Crispr Therapeutics AG Cash Flow

Cash Flow >

Crispr Therapeutics AG Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing